



Pharmaids Pharmaceuticals Limited

Date: 07-08-2025

To
The Corporate Relation Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400001

Dear Sir / Madam,

Scrip Code: 524572 | Scrip ID: PHARMAID | ISIN: INE117D01018

Subject: Outcome of Board Meeting held on August 07, 2025

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and in continuation to our intimation dated August 04, 2025 regarding the Notice for the Board Meeting, the Board of Directors of the Company in their Meeting held today i.e., Thursday, August 07, 2025, have, inter alia considered and approved the Unaudited Standalone and Consolidated Financial Results of the Company along with the Limited Review Report issued by the Statutory Auditors for the quarter ended June 30, 2025.

Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, a copy of results along with Limited Review Report thereon is enclosed herewith.

The Financial Results are also available on the website of the Company at www.pharmaids.com and on the website of BSE www.bseindia.com

The Board Meeting commenced at 03:30 P.M. and concluded at 04:20 P.M.

Kindly take the same on your record and oblige.

Thanking You

For Pharmaids Pharmaceuticals Limited

Prasanna Subramanya Bhat
(Company Secretary & Compliance Officer)

Independent Auditor's Review Report on unaudited quarterly standalone financial results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To,
The Board of Directors of
Pharmaids Pharmaceuticals Limited

Opinion

We have reviewed the accompanying statement of unaudited financial results of Pharmaids Pharmaceuticals Limited for the quarter ended 30th June 2025 ("the Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

Basis for Opinion

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Emphasis of Matter

We draw attention to Note 6 of the financial results, which describes a non-adjusting subsequent event that occurred after the reporting date 30 June 2025. The Board of Directors of the Company, at its meeting held on 04 July 2025, approved the disinvestment of the Company's entire 66.50% partnership stake in Anugraha Chemicals. In accordance with the applicable provisions of the Companies Act, 2013 and SEBI Listing Regulations, shareholders' approval is also being sought through a Postal Ballot Notice dated 04 July 2025. The e-voting process is currently ongoing and will conclude on 14 August 2025.

As approved in the resolution passed by the Board, the company entered into an enabling agreement with Anugraha Chemicals on 10 July 2025, to sell the stake to Mr. Sourabh Hadimani (existing partner) or his nominee subject to receipt of shareholders' approval.

This transaction occurred after the reporting date of 30 June 2025 and is classified as a non-adjusting subsequent event under Ind AS 10. As such, the financial results for the quarter have not been adjusted for this event. However, it has been disclosed in this report to provide stakeholders with relevant information regarding the Company's ongoing activities.

The Company's management believes that this event does not affect the financial position or performance for the period ending 30 June 2025.

Based on the limited review procedures performed, nothing has come to our attention that causes us to believe that the financial results for the quarter ended 30 June 2025 are not presented fairly, in all material respects, in accordance with the applicable accounting standards.

Our conclusion is not modified in respect of this matter.

For PPKG & Co.
Chartered Accountants
(Firm's Registration No. 009655S)

Swetha Toshniwal
(Partner)
(Membership No. 231499)

UDIN: 2523499BmH22A5299



Place: Hyderabad
Date: 7th August 2025

PHARMAIDS PHARMACEUTICALS LIMITED

CIN: L52520KA1989PLC173979


Reg Office: Unit 201, 2nd Floor, Brigade Rubix, 20/14 HMT Factory Main Road, Peenya Plantation Bangalore, Karnataka 560013, India.

Phone: 080-49784319, Email: compliance@pharmaids.com, Website: www.pharmaids.com

Statement of Unaudited Standalone Financial Results for the Quarter ended 30th June, 2025

All figures in Rs. Lacs unless otherwise specified

Particulars	Quarter ended Jun 30, 2025 (Unaudited)	Quarter ended Jun 30, 2024 (Unaudited)	Quarter ended Mar 31, 2025 (Audited)	Year ended Mar 31, 2025 (Audited)
Income				
Revenue from operations	111.53	16.65	13.25	234.09
Other income	34.72	0.31	100.68	101.89
Total income	146.25	16.96	113.93	335.98
Expenses				
Cost of materials consumed	5.94	-	2.99	3.01
Purchase of stock-in-trade	54.72	21.70	988.02	1,151.57
Changes in inventories of finished goods and work-in-progress	45.71	(6.70)	(976.52)	(953.60)
Employee benefits expense	139.74	73.96	109.49	341.82
Finance costs	111.06	1.27	205.36	214.91
Depreciation and amortisation expense	5.10	4.78	5.25	19.95
Other expenses	353.13	99.40	157.44	417.03
Total expenses	715.41	194.42	492.04	1,194.68
Profit/ (Loss) before exceptional items and tax	(569.17)	(177.46)	(378.11)	(858.70)
Exceptional items	0.03	-	-	-
Profit/ (Loss) before tax	(569.13)	(177.46)	(378.11)	(858.70)
Tax expense				
Current tax	-	-	-	-
Deferred tax	(132.83)	(15.12)	(72.47)	(130.78)
Total Tax Expense	(132.83)	(15.12)	(72.47)	(130.78)
Profit/ (Loss) for the year	(436.30)	(162.34)	(305.64)	(727.92)
Other comprehensive income				



PHARMAIDS PHARMACEUTICALS LIMITED

CIN: L52520KA1989PLC173979

Reg Office: Unit 201, 2nd Floor, Brigade Rubix, 20/14 HMT Factory Main Road, Peenya Plantation Bangalore, Karnataka 560013, India.

Phone: 080-49784319, Email: compliance@pharmaids.com, Website: www.pharmaids.com

Statement of Unaudited Standalone Financial Results for the Quarter ended 30th June, 2025


All figures in Rs. Lacs unless otherwise specified

Particulars	Quarter ended	Quarter ended	Quarter ended	Year ended
	Jun 30, 2025	Jun 30, 2024	Mar 31, 2025	Mar 31, 2025
	(Unaudited)	(Unaudited)	(Audited)	(Audited)
(i) Items that will not be reclassified subsequently to profit or loss				
Re-measurement on defined benefit plans and equity instruments	0.24	-	0.95	0.95
Income tax effect	(0.06)	-	(0.25)	(0.25)
(ii) Items that will be reclassified subsequently to profit or loss				
Effective portion of gains/(losses) on hedging instrument in cash flow hedges	-	-	-	-
Income tax effect	-	-	-	-
Other comprehensive income for the year, net of taxes	0.18	-	0.70	0.70
Total comprehensive income for the year	(436.12)	(162.34)	(304.93)	(727.22)
Paid-up Equity share capital (Face value Rs. 10/- per share)	3,526.78	3,526.78	3,526.78	3,526.78
Other Equity (excluding revaluation reserve)				2,852.10
Earnings per equity share				
Basic (in Rs)	(1.24)	(0.46)	(0.86)	(2.06)
Diluted (in Rs)	(1.24)	(0.46)	(0.86)	(2.06)

Place: Bengaluru

Date: 07-08-2025

By the order of the Board of Directors
For Pharmaids Pharmaceuticals Limited


Venu Madhava Kaparthy
 Whole Time Director
 DIN : 00021699



Notes to Accounts:

1. The above financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at its respective meetings held on August 07, 2025.
 2. The standalone financials results of the company have been prepared in accordance with the Ind AS as notified by the Ministry of Corporate Affairs pursuant to Section 133 of the Companies Act 2013 read with rule 3 of the Companies (Indian Accounting Standard) Rules 2015 (as amended) and in accordance with the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
 3. The figures for the quarters ended 31 March 2025 represents the balancing figures between audited figures in respect of the full financial year and published unaudited year to date figures upto nine months of the financial year, which were subject to limited review.
 4. The company operates in a single segment of providing Contract Research and Manufacturing Services.
 5. The figures for the previous periods have been regrouped / reclassified wherever considered necessary.
 6. The Board of Directors of the Company, at its meeting held on 04 July 2025, approved the disinvestment of the Company's entire 66.50% partnership stake in Anugraha Chemicals. In accordance with the applicable provisions of the Companies Act, 2013 and SEBI Listing Regulations, shareholders' approval is also being sought through a Postal Ballot Notice dated 04 July 2025. The e-voting process is currently ongoing and will conclude on 14 August 2025.
- As approved in the resolution passed by the Board, the company entered into an enabling agreement with Anugraha Chemicals on 10 July 2025, to sell the stake to Mr. Sourabh Hadimani (existing partner) or his nominee subject to receipt of shareholders' approval.

Place: Bengaluru
Date: 07-08-2025

**By the order of the Board of Directors
For Pharmaids Pharmaceuticals Limited**


Venu Madhava Kaparthy
Whole Time Director
DIN : 00021699



Independent Auditor's Review Report on unaudited quarterly consolidated financial results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To
The Board of Directors,
Pharmaids Pharmaceuticals Limited (Holding Company)

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of Pharmaids Pharmaceuticals Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net profit/(loss) after tax and total comprehensive income / loss of its subsidiaries for the quarter ended 30th June 2025 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.
4. The Statement includes the results of the following entities:
 - i. Adit Bio Sys Private Limited
 - ii. Siri Labvivo Diet Private Limited
 - iii. Anugraha Chemicals
 - iv. Spring Labs
5. We draw attention to Note 6 of the financial results, which describes a non-adjusting subsequent event that occurred after the reporting date 30 June 2025. The Board of Directors of the Company, at its meeting held on 04 July 2025, approved the disinvestment of the Company's entire 66.50% partnership stake in Anugraha Chemicals. In accordance with the applicable provisions of the Companies Act, 2013 and SEBI Listing Regulations, shareholders' approval is also being sought through a Postal Ballot Notice dated 04 July 2025. The e-voting process is currently ongoing and will conclude on 14 August 2025.

As approved in the resolution passed by the Board, the company entered into an enabling agreement with Anugraha Chemicals on 10 July 2025, to sell the stake to Mr. Sourabh Hadimani (existing partner) or his nominee subject to receipt of shareholders' approval.

This transaction occurred after the reporting date of 30 June 2025 and is classified as a non-adjusting subsequent event under Ind AS 10. As such, the financial results for the quarter have not been adjusted for this event. However, it has been disclosed in this report to provide stakeholders with relevant information regarding the Company's ongoing activities.

The Company's management believes that this event does not affect the financial position or performance for the period ending 30 June 2025.

6. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the branch auditors and other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

We did not review the interim financial results of 2 subsidiaries included in the consolidated unaudited financial results, whose interim financial statements / financial information / financial results reflect total revenues of Rs. 554.83 Lakhs, total net profit/(loss) after tax of Rs. (152.93) Lakhs for the quarter ended 30th June 2025, as considered in the consolidated unaudited financial results.

These interim financial statements / financial information / financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Consolidated Financial Statement is not modified in respect of the above matters.

For PPKG & Co.

Chartered Accountants

(Firm's Registration No. 009655S)

Swetha Toshniwal
(Partner)

(Membership No. 231499)

UDIN: 26231499BMH2Y25830



Place: Hyderabad

Date: 7th August 2025

PHARMAIDS PHARMACEUTICALS LIMITED

CIN: L52520KA1989PLC173979

Reg Office: Unit 201, 2nd Floor, Brigade Rubix, 20/14 HMT Factory Main Road, Peenya Plantation Bangalore, Karnataka 560013, India.

Phone: 080-49784319, Email: compliance@pharmaids.com, Website: www.pharmaids.com

Statement of Unaudited Consolidated Financial Results for the Quarter ended 30th June, 2025

All figures in Rs. Lacs unless otherwise specified

Particulars	Quarter ended Jun 30, 2025 (Unaudited)	Quarter ended Jun 30, 2024 (Unaudited)	Quarter ended Mar 31, 2025 (Audited)	Year ended Mar 31, 2025 (Audited)
Income				
Revenue from operations	666.36	473.07	476.80	1,944.74
Other income	4.01	0.94	7.40	10.40
Total income	670.37	474.02	484.21	1,955.14
Expenses				
Cost of materials consumed	191.85	287.16	178.36	932.44
Purchase of stock-in-trade	123.19	33.47	1,036.24	1,279.08
Changes in inventories of finished goods and work-in-progress	35.53	68.22	(997.29)	(928.69)
Employee benefits expense	418.76	299.20	405.18	1,316.24
Finance costs	119.55	26.13	100.71	208.76
Depreciation and amortisation expense	60.62	56.59	62.05	244.02
Other expenses	438.00	125.72	245.12	621.44
Total expenses	1,387.49	896.50	1,030.39	3,673.29
Profit/ (Loss) before exceptional items and tax	(717.12)	(422.48)	(546.18)	(1,718.15)
Exceptional items	0.03	(7.63)	5.99	(9.78)
Profit/ (Loss) before tax	(717.08)	(430.11)	(540.20)	(1,727.93)
Tax expense				
Current tax	-	-	-	-
Tax paid for earlier years	-	-	-	6.29
Deferred tax	(185.55)	(117.66)	(59.89)	(383.70)
Total Tax Expense	(185.55)	(117.66)	(59.89)	(377.41)
Profit/ (Loss) for the year	(531.53)	(312.45)	(480.31)	(1,350.51)
Other comprehensive income				
(i) Items that will not be reclassified subsequently to profit or loss				
Re-measurement on defined benefit plans and equity instruments	1.11	-	2.19	2.19
Income tax effect	(0.21)	-	(0.15)	(0.15)
(ii) Items that will be reclassified subsequently to profit or loss				
Effective portion of gains/(losses) on hedging instrument in cash flow hedges	-	-	-	-
Income tax effect	-	-	-	-
Other comprehensive income for the year, net of taxes	0.90	-	2.05	2.05
Total comprehensive income for the year	(530.64)	(312.45)	(478.26)	(1,348.47)



[Handwritten signature]

PHARMAIDS PHARMACEUTICALS LIMITED

CIN: L52520KA1989PLC173979

Reg Office: Unit 201, 2nd Floor, Brigade Rubix, 20/14 HMT Factory Main Road, Peenya Plantation Bangalore, Karnataka 560013, India.

Phone: 080-49784319, Email: compliance@pharmaids.com, Website: www.pharmaids.com

Statement of Unaudited Consolidated Financial Results for the Quarter ended 30th June, 2025

All figures in Rs. Lacs unless otherwise specified

Particulars	Quarter ended Jun 30, 2025 (Unaudited)	Quarter ended Jun 30, 2024 (Unaudited)	Quarter ended Mar 31, 2025 (Audited)	Year ended Mar 31, 2025 (Audited)
Profit/ (Loss) attributable to:				
Equity holders of the Holding company	(495.14)	(268.44)	(393.88)	(1,077.66)
Non-controlling interest	(36.39)	(44.02)	(86.43)	(272.85)
Profit/ (Loss) for the year	(531.53)	(312.45)	(480.30)	(1,350.51)
Other comprehensive income attributable to:				
Equity holders of the Holding company	(0.84)	-	2.03	2.04
Non-controlling interest	1.74	-	0.01	0.01
Other comprehensive income for the year	0.90	-	2.04	2.05
Total comprehensive income attributable to:				
Equity holders of the Holding company	(495.99)	(268.44)	(391.85)	(1,075.62)
Non-controlling interest	(34.65)	(44.02)	(86.42)	(272.84)
Total comprehensive income for the year	(530.64)	(312.45)	(478.26)	(1,348.47)
Paid-up Equity share capital (Face value Rs. 10/- per share)	3,526.78	3,526.78	3,526.78	3,526.78
Other Equity (excluding revaluation reserve)				2,405.25
Earnings per equity share				
Basic (in Rs)	(1.41)	(0.76)	(1.11)	(3.05)
Diluted (in Rs)	(1.41)	(0.76)	(1.11)	(3.05)

Place: Bengaluru

Date: 07-08-2025

By the order of the Board of Directors
For Pharmaids Pharmaceuticals Limited

Venu Madhava Kaparthy
Whole Time Director
DIN : 00021699




Notes to Accounts:

1. The Consolidated Financial Results of Pharmaids(The Holding Company) and its subsidiaries (together referred to as Group) have been prepared in accordance with the Indian Accounting Standards (Ind-AS) as prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and relevant amendment rules thereafter and in accordance with the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. The Consolidated Financial Results have been reviewed by the Audit Committee and approved by the Board of Directors of the Holding Company at their respective Meetings held on August 07, 2025 and have been reviewed by the Statutory Auditors of the Holding Company.
3. The figures for the quarter ended 31 March 2025 represents the balancing figures between audited figures in respect of the full financial year and
4. The group operates in a single segment of providing Contract Research and Manufacturing Services.
5. The figures for the previous periods have been regrouped / reclassified wherever considered necessary.
6. The Board of Directors of the Company, at its meeting held on 04 July 2025, approved the disinvestment of the Company's entire 66.50% partnership stake in Anugraha Chemicals. In accordance with the applicable provisions of the Companies Act, 2013 and SEBI Listing Regulations, shareholders' approval is also being sought through a Postal Ballot Notice dated 04 July 2025. The e-voting process is currently ongoing and will conclude on 14 August 2025.
As approved in the resolution passed by the Board, the company entered into an enabling agreement with Anugraha Chemicals on 10 July 2025, to sell the stake to Mr. Sourabh Hadimani (existing partner) or his nominee subject to receipt of shareholders' approval.

Place: Bengaluru
Date: 07-08-2025

**By the order of the Board of Directors
For Pharmaids Pharmaceuticals Limited**


Venu Madhava Kaparthy
Whole Time Director
DIN : 00021699

